Tenax Therapeutics (TENX) Restructuring Costs (2012 - 2013)

Tenax Therapeutics (TENX) reported Restructuring Costs of $2941.0 for Q1 2013, down 98.27% sequentially from $170298.0 in Q4 2012.

Tenax Therapeutics (TENX) Restructuring Costs (2012 - 2013) Analysis & Trends

Tenax Therapeutics (TENX) has 2 years of Restructuring Costs data on file, last reported at $2941.0 in Q1 2013.

For the quarter ending Q1 2013, Restructuring Costs changed N/A year-over-year to $2941.0; the trailing twelve-month figure through Apr 2013 stood at $220715.0 (changed N/A YoY), and the FY2013 full-year result was $220715.0, changed N/A from the prior year.
Restructuring Costs declined to $2941.0 in Q1 2013, from $170298.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $170298.0 in Q4 2012 to a low of $2941.0 in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Tenax Therapeutics	655.78 Mn	655.78 Mn	-

Download Data